Back to GetFilings.com





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the quarterly period ended June 30, 2004

or

[_] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the Transition Period From ___________ to ___________

Commission file number 0-30318

VENTIV HEALTH, INC.
(Exact name of registrant as specified in its charter)

    Delaware                      52-2181734
(State or other jurisdiction             (IRS Employer
of incorporation or organization)         Identification No.)

200 Cottontail Lane
Vantage Court North
Somerset, New Jersey 08873
(Address of principal executive office and zip code)

(800) 416-0555
(Registrant's telephone number, including area code)

Indicate by check mark whether Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [_]

        Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Yes [X] No [ ]

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Common Stock, par value $0.001, 23,814,840 shares outstanding as of July 30, 2004



 
     

 
 

VENTIV HEALTH, INC.
INDEX TO QUARTERLY REPORT ON
FORM 10-Q

 
Page
PART I. FINANCIAL INFORMATION
 
 
 
ITEM 1. Financial Statements
 
     
 
   Consolidated Balance Sheets as of June 30, 2004 and December 31, 2003 (unaudited)
1
 
 
   Consolidated Statements of Operations for the three and six months ended June 30, 2004 and 2003 (unaudited)
       2
    
 
   Consolidated Statements of Cash Flows for the six months ended June 30, 2004 and 2003 (unaudited)
3
 
 
   Notes to Consolidated Financial Statements (unaudited)
4 - 10
 
 
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
11 - 19
 
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
20
 
ITEM 4. Controls and Procedures
20
 
 
PART II. OTHER INFORMATION
 
 
 
ITEM 1. Legal Proceedings
21
 
 
ITEM 4. Submission of Matters to a Vote of Security Holders
21
 
 
ITEM 6. Exhibits and Reports on Form 8-K
22
 
 
SIGNATURES
23
 
 
EXHIBITS
24 – 27

 
   

 
 

PART I. FINANCIAL INFORMATION

ITEM 1.   Financial Statements

VENTIV HEALTH, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share amounts)
(unaudited)
 
June 30,
December 31,
 
2004
2003


 
 
 
ASSETS
 
 
Current assets:
 
 
Cash and equivalents
$78,486
$54,970
Restricted cash
3,903
1,672
Accounts receivable, net of allowances for doubtful accounts of $1,693
 
 
    and $2,019 at June 30, 2004 and December 31, 2003, respectively
33,249
41,836
Unbilled services
24,645
21,347
Prepaid expenses and other current assets
3,423
1,146
Current deferred tax assets
1,660
1,660
 

  
Total current assets
145,366
122,631
Property and equipment, net
30,411
31,457
Goodwill
26,644
20,638
Other intangibles, net
2,632
85
Deferred tax assets
5,438
5,438
Other assets
707
459


Total assets
$211,198
$180,708


 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
Current liabilities:
 
 
Current portion of capital lease obligations
$9,858
$8,100
Accrued payroll, accounts payable and accrued expenses
35,828
32,105
Current income tax liabilities
14,681
9,165
Client advances and unearned revenue
6,723
4,859
 
  

  
Total current liabilities
67,090
54,229
Capital lease obligations
19,143
18,488
Other non-current liabilities
270
266


Total liabilities
86,503
72,983


 
 
 
Commitments and contingencies
 
 
 
 
 
Stockholders' Equity:
 
 
Preferred stock, $.001 par value, 10,000,000 shares authorized, none issued
 
 
and outstanding at June 30, 2004 and December 31, 2003
Common stock, $.001 par value, 50,000,000 shares authorized; 23,814,590 and
 
 
23,094,503 shares issued and outstanding at June 30, 2004 and
 
 
December 31, 2003, respectively
24
23
Additional paid-in-capital
164,573
159,359
Deferred compensation
(61)
(85)
Accumulated other comprehensive earnings
122
103
Accumulated deficit
(39,963)
(51,675)


Total stockholders' equity
124,695
107,725


Total liabilities and stockholders' equity
$211,198
$180,708



The accompanying notes are an integral part of these consolidated financial statements
 
1  

 
VENTIV HEALTH, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)
(unaudited)
 
For the Three Months
For the Six Months
 
Ended June 30,
Ended June 30,


 
2004
2003
         2004
      2003




Revenues
$75,221
$46,239
$145,882
$89,893
Operating expenses:
 
 
 
 
Cost of services
60,297
37,984
116,607
75,840
Selling, general and administrative expenses
7,299
5,802
13,570
11,234
Restructuring
(264)
--
(264)
--
Gain on sale of real estate
--
(392)
--
(392)




Total operating expenses
67,332
43,394
129,913
86,682
 

 

 

 

 
Operating earnings
7,889
2,845
15,969
3,211
Interest expense
(200)
(139)
(381)
(246)
Interest income
142
122
225
226




Earnings from continuing operations before income taxes
7,831
2,828
15,813
3,191
Income tax provision
2,976
1,075
6,009
1,212




Earnings from continuing operations
4,855
1,753
9,804
1,979




 
 
 
 
 
Earnings (losses) from discontinued and held for sale operations:
 
 
 
 
Losses from discontinued operations, net of taxes
--
(2,786)
--
(3,629)
Gains (losses) on disposals of discontinued operations, net of taxes
1,754
(799)
1,908
(1,353)
Net earnings (losses) from discontinued operations
1,754
(3,585)
1,908
(4,982)




 
 
 
 
 
Net earnings (losses)
$6,609
$(1,832)
$11,712
$(3,003)




 
 
 
 
 
Earnings (losses) per share:
 
 
 
 
Continuing operations:
 
 
 
 
Basic
$0.21
$0.08
$0.42
$0.09
Diluted
$0.19
$0.07
$0.39
$0.08
Discontinued operations:
 
 
 
 
Basic
$0.07
$(0.16)
$0.08
$(0.22)
Diluted
$0.07
$(0.15)
$0.08
$(0.21)
Net earnings (losses):
 
 
 
 
Basic
$0.28
$(0.08)
$0.50
$(0.13)
Diluted
$0.26
$(0.08)
$0.47
$(0.13)
Weighted average number of common shares outstanding:
 
 
 
 
Basic
23,546
22,887
23,353
22,889
Diluted
25,297
23,575
24,933
23,381

The accompanying notes are an integral part of these consolidated financial statements

 
2  

 
VENTIV HEALTH, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)
(unaudited)
 
For the Six Months Ended June 30,

 
2004
2003


Cash flows from operating activities:
 
Net earnings (losses)
$11,712
$(3,003)
Adjustments to reconcile net earnings (losses) to net cash provided by operating activities:
 
 
(Earnings) losses from discontinued operations
(1,908)
4,982
Depreciation
7,544
4,258
Amortization
9
9
Gain on sale of real estate
--
(392)
Stock compensation expense
45
264
Executive share surrender
--
(185)
Changes in assets and liabilities, net of effects from discontinued operations:
 
 
Restricted cash
(1,231)
270
Accounts receivable, net
10,575
10,977
Unbilled services
(2,128)
3,250
Prepaid expenses and other current assets
(2,269)
(843)
Accrued payroll, accounts payable and accrued expenses
1,866
(1,943)
Current income tax liabilities
5,516
1,219
Client advances and unearned revenue
1,840
5,110
Other
(269)
501


Net cash provided by operating activities
31,302
24,474


 
 
 
Cash flows from investing activities:
 
 
Cash paid for acquisition of Franklin Group, Inc. and Lincoln, Ltd., Inc.
(6,667)
--
Proceeds from disposals of discontinued operations
701
1,202
Proceeds from sale of real estate
--
1,099
Purchases of property and equipment
(2,111)
(1,213)
Proceeds from manufacturers’ rebates on leased vehicles
3,479
--


Net cash (used in) provided by investing activities
(4,598)
1,088


 
 
 
Cash flows from financing activities:
 
 
Collateralization of obligations under standby letter of credit
(1,000)
(788)
Repayments of capital lease obligations
(5,026)
(2,287)
Proceeds from exercise of stock options
1,612
3
 
  

  
Net cash used in financing activities
(4,414)
(3,072)


 
 
 
Net cash provided by (used in) discontinued operations
1,207
(3,053)


Effect of exchange rate changes
19
615


 
 
 
Net increase in cash and equivalents
23,516
20,052
Cash and equivalents, beginning of period
54,970
46,059


Cash and equivalents, end of period
$78,486
$66,111


 
 
 
Supplemental disclosures of cash flow information:
 
 
Cash paid for interest
$381
$259
Cash paid for income taxes
$682
$284
Supplemental disclosure of non-cash activities: